Jagsonpal Pharmaceuticals Limited has informed the Exchange about Transcript
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported strong Q1FY26 results with revenue up 23% YoY at Rs. 75.5 crore, driven by 9-10% organic growth and full-quarter benefit from the Yash Pharma acquisition. Gross margins expanded 80 bps to 64.4%, and operating EBITDA (before ESOP) grew 24% to Rs. 157 million with margins at 20.8%. Profit after tax doubled to over Rs. 108 million, with net margins improving 560 bps to 14.3%. The company ended the quarter with a strong cash balance of Rs. 161 crore and maintained its annual guidance of 15% revenue growth and 100-150 bps EBITDA margin expansion. Management also disclosed that the CFO, Sachin Jain, was terminated in July 2025 during probation for misconduct and misrepresentation.
Positive quarter with broad-based growth, margin expansion, and healthy cash generation supports the bull case. Strong cash position of Rs. 161 crore provides flexibility for inorganic growth or shareholder returns. The CFO termination for governance reasons may raise short-term concerns but signals strong ethical standards. Full-year guidance reaffirmed.